McAdam LLC’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

McAdam LLC’s Portfolio SRNE Stock Details SRNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-200	Closed	-$1K	–	669
2018 Q3	$1K	Buy	+200	New	+$1.11K	﹤0.01%	641

Other funds holding SRNE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

McAdam LLC's SRNE Position: Q4 2018 in Review

McAdam LLC sold out of Sorrento Therapeutics, Inc. (SRNE) in Q4 2018, closing a stake of 200 shares — an estimated $1K sold.

McAdam LLC first reported a position in SRNE in Q3 2018 and held it in 1 quarter. The position peaked at $1K in Q3 2018. 78 funds tracked by Wall St. Rank hold SRNE as of Q4 2018.

McAdam LLC reported no remaining Sorrento Therapeutics, Inc. position as of Q4 2018 after selling out during the quarter.
McAdam LLC sold 200 Sorrento Therapeutics, Inc. shares in Q4 2018, an estimated $1K.
McAdam LLC first reported a position in Sorrento Therapeutics, Inc. in Q3 2018 and held it in 1 quarter.
McAdam LLC's Sorrento Therapeutics, Inc. position peaked at $1K in Q3 2018.
78 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q4 2018.

Based on McAdam LLC's 13F filing for Q4 2018, filed 30 Jan 2019.